Deviation – Page 39 – Pharma.Tips

Unauthorized method modification during FDA inspection – inspection citation explained

Unauthorized Method Modification during FDA Audit: A Case Study on Addressing Noncompliance During a routine FDA inspection, a pharmaceutical company encountered a significant setback when inspectors identified unauthorized modifications to…

Unapproved chromatographic integration during stability analysis – inspection citation explained

Addressing Unapproved Chromatographic Integration During Stability Analysis: A Case Study In the ever-evolving pharmaceutical landscape, ensuring compliance with Good Manufacturing Practices (GMP) and maintaining data integrity is paramount. This case…

System suitability failure ignored during method transfer – CAPA failure exposed

Addressing System Suitability Failures During Method Transfer: A CAPA Case Study In a recent case study, a pharmaceutical manufacturing facility experienced significant issues during the transfer of analytical methods, which…

OOS invalidated without justification during investigation – CAPA failure exposed

Addressing the OOS Invalidated Without Justification During Investigation: A Comprehensive Case Study In a highly-regulated pharmaceutical environment, it is critical to manage deviations meticulously to uphold product quality and compliance.…

Backdated test records during method transfer – data integrity breach analysis

Analyzing Data Integrity Breaches: A Case Study of Backdated Test Records in Method Transfer In the rigorous world of pharmaceutical manufacturing, data integrity is a non-negotiable linchpin of compliance and…

Unauthorized method modification during stability analysis – CAPA failure exposed

Unauthorized Modifications to Stability Analysis Methods: A Case Study in CAPA Failures In pharmaceutical production, maintaining the integrity of analytical methods is crucial. Imagine a scenario where a Quality Control…

Process change implemented without QA approval during changeover – regulatory impact assessment case study

Case Study: Unauthorized Process Change During Changeover and Its Regulatory Implications In the dynamic landscape of pharmaceutical manufacturing, adherence to established protocols is paramount. This case study highlights a scenario…

Batch executed with expired SOP during routine manufacturing – FDA inspection observation breakdown

Investigation of a Batch Executed Using Expired SOPs in Pharmaceutical Manufacturing On a routine day at a biotech manufacturing facility, quality assurance (QA) staff noticed an acute deviation: a batch…

Critical IPC skipped during changeover – root cause analysis failure explained

Root Cause Analysis of Skipped Critical IPC During Changeover in Pharmaceutical Manufacturing In a typical pharmaceutical manufacturing environment, adherence to protocols is paramount for ensuring product quality and regulatory compliance.…

Critical IPC skipped during routine manufacturing – root cause analysis failure explained

Analyzing the Impact of Missed Critical IPC During Routine Manufacturing In a recent scenario at a pharmaceutical manufacturing facility, an important in-process control (IPC) step was skipped during routine batch…

Equipment used without release during tech transfer – CAPA ineffectiveness identified

Investigating the Use of Equipment Without Release During Tech Transfer: A Case Study In the world of pharmaceutical manufacturing, deviations can lead to significant regulatory implications and quality issues. A…

Equipment used without release during commercial campaign – FDA inspection observation breakdown

Case Study on Equipment Acted Upon Without Release During a Commercial Campaign In the pharmaceutical manufacturing sector, deviations from established protocols can lead to severe quality control issues and regulatory…